Skip to contentK
Kyntra Bio, Inc.
K
KYNBKyntra Bio, Inc. Q4 2021 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$16.54M$16.54Mderived−74.5% vs Q4 2020 Net Income-$134.08M-$134.08MderivedN/M vs Q4 2020 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Kyntra Bio, Inc. · CIK 921299 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$135,242,000N/M Operating Cash Flowderived-$54,960,000N/M Free Cash Flowderived-$56,356,000N/M Margins · derivedOperating margin-817.5%−728.3 pt vs Q4 2020
Net margin-810.5%−720.3 pt vs Q4 2020
ended Dec 31, 2021 · filed Feb 28, 2022 · 59 d after period end